Home - Blacksmith Medicines
Purpose-Built Platform forMetalloenzyme-Targeted Medicines. Blacksmith Medicines. 3033 Science Park Road Suite 270 San Diego, CA 92121 | Media: amy@juniper-point.com.
About Us - Blacksmith Medicines
At Blacksmith Medicines, we seek to honor that age-old tradition of hard-work and invention through the discovery and development of small molecule inhibitors of metal-dependent …
Technology - Blacksmith Medicines
Technology. Blacksmith Medicines has developed a purpose-built platform focused on the discovery and development of small molecule inhibitors of metal-dependent enzymes. Over …
Blacksmith Medicines and Zoetis Announce Research …
2024年2月14日 · Blacksmith has executed strategic drug discovery collaborations with Basilea Pharmaceutica International Ltd., Cyteir Therapeutics Inc., Eli Lilly and Company (Lilly), …
Pipeline & Targets - Blacksmith Medicines
Novel oncology & infectious disease medicines supported by multiple pharma partners & Federal government. Target strategy: Important targets that have been challenging to drug due to …
Blacksmith Medicines announces merger with Forge Therapeutics …
2023年1月2日 · SAN DIEGO, California, January 2, 2023 – Blacksmith Medicines, Inc. (Blacksmith), and Forge Therapeutics (Forge), announce today that the companies have …
Blacksmith Medicines launches with seed funding and a research ...
SAN DIEGO, California, January 8, 2021 – Blacksmith Medicines, Inc. (Blacksmith), a biotechnology company focused on creating novel medicines for immuno-oncology and …
Blacksmith Medicines Announces $3.3M in Funding from NIAID to …
2024年2月21日 · Blacksmith, using its proprietary chemistry platform, has developed novel non-hydroxamate inhibitors of LpxC that are safe and effective in animal models of Gram-negative …
Press Releases - Blacksmith Medicines
2023年1月5日 · Blacksmith Medicines Announces $3.3M in Funding from NIAID to Support Clinical Trial Manufacturing of Novel Antibiotic.
Forge Therapeutics awarded up to $17.2 million ... - Blacksmith …
2022年9月29日 · Forge, using its proprietary metal-binding pharmacophore chemistry platform, has developed novel, non-hydroxamate-based LpxC inhibitors that are safe and effective in …